NCT04782076View on ClinicalTrials.gov

A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

May 17, 2021

Study Completion Date

May 17, 2021

Conditions
Healthy
Interventions
DRUG

Dabigatran

Administered orally.

DRUG

Selpercatinib

Administered orally.

Trial Locations (1)

32117

Covance Clinical Research Inc, Daytona Beach

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Loxo Oncology, Inc.

INDUSTRY

NCT04782076 - A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants | Biotech Hunter | Biotech Hunter